Company Overview
Monopar Therapeutics Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapeutics designed for the treatment of cancer within the United States market. The firm focuses on its pipeline assets, specifically ALXN1840, which is an investigational once-daily oral medicine in late-stage development, and MNPR-101, a proprietary humanized monoclonal antibody. This entity functions within the broader Healthcare sector, specifically the Biotechnology industry, positioning it as an entity that relies heavily on research and development rather than established commercial product sales. The company currently maintains a market capitalization of $380.57M and employs a workforce of 14 individuals to advance its scientific initiatives. These valuation and staffing metrics indicate that the company is a relatively small-scale biotechnology venture, typical for clinical-stage firms that have not yet generated significant commercial revenue to offset their operational expenditures.
Financial Health
The company reports N/A for annual revenue under the trailing twelve-month period, while posting a net income of $-19,441,708 and an EBITDA figure that is not available. The absence of positive revenue coupled with a substantial net loss reveals a cost structure driven primarily by research and development expenses and operational overhead rather than sales costs. Monopar Therapeutics Inc. demonstrates a free cash flow of $-8,453,437, which signifies that the company is burning cash to fund its clinical trials and development programs, thereby limiting its immediate financial flexibility without access to external capital. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a status that indicates the company is currently in a pre-revenue phase where no commercial sales exist to generate profitability. In terms of balance sheet composition, the company holds $143.68M in cash against $102,236 in debt, resulting in a debt-to-equity ratio of 0.07. This disparity between cash holdings and debt obligations suggests a conservative balance sheet structure with minimal leverage. Furthermore, the current ratio stands at 56.10, which indicates an exceptionally strong short-term liquidity position relative to its liabilities. Finally, the return on equity is -26.5% and the return on assets is -18.0%, metrics that reveal that the management team is currently utilizing shareholder and asset bases to generate negative returns due to the lack of profitable operations.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A, while the forward P/E is listed as -16.35, implying that the market is pricing in future earnings potential based on negative current earnings rather than historical profitability. The price-to-book ratio is 2.68, which indicates that the stock is trading at a significant premium over its tangible book value, a common characteristic for biotechnology firms with valuable intellectual property despite current losses. The price-to-sales ratio is N/A, and the EV/EBITDA is also N/A, suggesting that traditional valuation multiples based on sales or earnings are not applicable until the company achieves commercial revenue generation. Regarding price action, the 52-week high is $105.00 and the 52-week low is $26.05, placing the current market price within the lower to middle range of this trading band relative to the annual volatility observed. The beta value is 1.67, which means the stock exhibits higher price volatility relative to the broader market, reacting more aggressively to market movements than the average large-cap equity.
Growth & Income
The revenue growth year-over-year is N/A, and the earnings growth year-over-year is also N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated. Since the company has not generated positive earnings, there is no dividend yield available, and the payout ratio is 0.0%, indicating that the firm does not distribute cash to shareholders. Instead of paying dividends, the company reinvests all available earnings and cash reserves directly into its drug development programs and clinical trial infrastructure. Consequently, the overall growth and income profile is characterized by a complete absence of current income generation, with all financial focus directed toward advancing the clinical status of its oncology therapeutics.